Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 + Bevacizumab vs Sacituzumab Tirumotecan in Advanced Non-squamous NSCLC
NCT07895992Phase 3Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of ruzaltatug rezetecan in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ruzaltatug rezetecan
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07895992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895992.